Evidence map›Paper›PMID 41694200›Full record

ArticleEndocrine oncology (Bristol, England)2026

Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis.

Giuseppe Lamberti, Francesco Panzuto, Maria Rinzivillo, Flaminia Benedetta Zoboli, Irene Zannini, Elisa Andrini, Elisabetta Dell'Unto, Riccardo Di Pangrazio, Davide Campana

Abstract read
In one paragraph

Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giuseppe LambertiDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0003-3069-7630
Francesco PanzutoDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza Università di Roma, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.
Maria RinzivilloDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza Università di Roma, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.
Flaminia Benedetta ZoboliDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Irene ZanniniDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Elisa AndriniDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Elisabetta Dell'UntoDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza Università di Roma, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.
Riccardo Di PangrazioDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza Università di Roma, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.
Davide CampanaDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0002-4615-7340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The prognostic value of primary tumor size in duodenal neuroendocrine neoplasms (dNENs) ≤20 mm remains uncertain. Although size is used to guide management, its independent effect on survival is unclear. Design and methods: We performed a population-based study using the US SEER database (1975-2021), including adults with histologically confirmed dNENs ≤20 mm. Disease-specific survival (DSS) was the primary endpoint. Associations between tumor size, stage, lymph-node involvement, and DSS were evaluated using chi-squared tests, logistic regression, Kaplan-Meier curves, and Cox models. Receiver operating characteristic (ROC) analysis identified the optimal size cutoff. Mediation analysis assessed whether stage or grade mediated the size-DSS relationship. Results: Among 3,515 eligible cases, median age was 65 years, 51% were male, and 89% had well-differentiated NETs. Most tumors were localized (85.2%) and ≤10 mm (74.4%). Median follow-up was 56 months, with 160 disease-specific deaths (4.6%). In univariable analysis, size >10 mm was associated with worse DSS, but the association disappeared after adjustment for grade, stage, and surgery. Grade G3 and advanced stage independently predicted poorer survival, while radical surgery was protective. Larger tumors were more frequently high grade and advanced stage ( Conclusions: In duodenal NENs ≤ 20 mm, tumor size >10 mm correlates with disease extent but does not independently affect DSS, supporting its role as a stratification marker rather than a prognostic factor.

Indexed as

duodenal neuroendocrine neoplasmsendoscopic resectionlymph-node metastasisSEERtumor size

Identifiers

PMID41694200
PMCPMC12895395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.